Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 81

1.

Assessment on marine litter ingested by fish in the Adriatic and NE Ionian Sea macro-region (Mediterranean).

Anastasopoulou A, Kovač Viršek M, Bojanić Varezić D, Digka N, Fortibuoni T, Koren Š, Mandić M, Mytilineou C, Pešić A, Ronchi F, Šiljić J, Torre M, Tsangaris C, Tutman P.

Mar Pollut Bull. 2018 Aug;133:841-851. doi: 10.1016/j.marpolbul.2018.06.050. Epub 2018 Jun 26.

PMID:
30041385
2.

Anthropogenic microfibres pollution in marine biota. A new and simple methodology to minimize airborne contamination.

Torre M, Digka N, Anastasopoulou A, Tsangaris C, Mytilineou C.

Mar Pollut Bull. 2016 Dec 15;113(1-2):55-61. doi: 10.1016/j.marpolbul.2016.07.050. Epub 2016 Aug 1.

PMID:
27491365
3.

Diet and feeding strategy of blackmouth catshark Galeus melastomus.

Anastasopoulou A, Mytilineou Ch, Lefkaditou E, Dokos J, Smith CJ, Siapatis A, Bekas P, Papadopoulou KN.

J Fish Biol. 2013 Dec;83(6):1637-55. doi: 10.1111/jfb.12269. Review.

PMID:
24298955
4.

Spatial distribution and life-history aspects of blackspot seabream Pagellus bogaraveo (Osteichthyes: Sparidae).

Mytilineou Ch, Tsagarakis K, Bekas P, Anastasopoulou A, Kavadas S, Machias A, Haralabous J, Smith CJ, Petrakis G, Dokos J, Kapandagakis A.

J Fish Biol. 2013 Dec;83(6):1551-75. doi: 10.1111/jfb.12271. Review.

PMID:
24298951
5.

Inhibition of proteasome activity sensitizes dopamine neurons to protein alterations and oxidative stress.

Mytilineou C, McNaught KS, Shashidharan P, Yabut J, Baptiste RJ, Parnandi A, Olanow CW.

J Neural Transm (Vienna). 2004 Oct;111(10-11):1237-51.

PMID:
15480836
6.

Levodopa in the treatment of Parkinson's disease: current controversies.

Olanow CW, Agid Y, Mizuno Y, Albanese A, Bonuccelli U, Damier P, De Yebenes J, Gershanik O, Guttman M, Grandas F, Hallett M, Hornykiewicz O, Jenner P, Katzenschlager R, Langston WJ, LeWitt P, Melamed E, Mena MA, Michel PP, Mytilineou C, Obeso JA, Poewe W, Quinn N, Raisman-Vozari R, Rajput AH, Rascol O, Sampaio C, Stocchi F.

Mov Disord. 2004 Sep;19(9):997-1005. Review. Erratum in: Mov Disord. 2005 May;20(5):645. Bonucelli, U [corrected to Bonuccelli, Ubaldo].

PMID:
15372588
8.

Toxicity of glutathione depletion in mesencephalic cultures: a role for arachidonic acid and its lipoxygenase metabolites.

Kramer BC, Yabut JA, Cheong J, Jnobaptiste R, Robakis T, Olanow CW, Mytilineou C.

Eur J Neurosci. 2004 Jan;19(2):280-6.

PMID:
14725622
9.

Levodopa is toxic to dopamine neurons in an in vitro but not an in vivo model of oxidative stress.

Mytilineou C, Walker RH, JnoBaptiste R, Olanow CW.

J Pharmacol Exp Ther. 2003 Feb;304(2):792-800.

PMID:
12538835
10.

Glutathione depletion and oxidative stress.

Mytilineou C, Kramer BC, Yabut JA.

Parkinsonism Relat Disord. 2002 Sep;8(6):385-7. Review.

PMID:
12217624
11.

Lipopolysaccharide prevents cell death caused by glutathione depletion: possible mechanisms of protection.

Kramer BC, Yabut JA, Cheong J, JnoBaptiste R, Robakis T, Olanow CW, Mytilineou C.

Neuroscience. 2002;114(2):361-72.

PMID:
12204205
12.

Impairment of the ubiquitin-proteasome system causes dopaminergic cell death and inclusion body formation in ventral mesencephalic cultures.

McNaught KS, Mytilineou C, Jnobaptiste R, Yabut J, Shashidharan P, Jennert P, Olanow CW.

J Neurochem. 2002 Apr;81(2):301-6.

13.
14.

Glial cells mediate toxicity in glutathione-depleted mesencephalic cultures.

Mytilineou C, Kokotos Leonardi ET, Kramer BC, Jamindar T, Olanow CW.

J Neurochem. 1999 Jul;73(1):112-9.

15.

Cell culture models of neuronal degeneration and neuroprotection. Implications for Parkinson's disease.

Leonardi ET, Mytilineou C.

Adv Exp Med Biol. 1998;446:203-22. Review. No abstract available.

PMID:
10079845
16.

Current status of selegiline as a neuroprotective agent in Parkinson's disease.

Olanow CW, Mytilineou C, Tatton W.

Mov Disord. 1998;13 Suppl 1:55-8. Review. No abstract available.

PMID:
9613720
17.

Deprenyl and desmethylselegiline protect mesencephalic neurons from toxicity induced by glutathione depletion.

Mytilineou C, Leonardi EK, Radcliffe P, Heinonen EH, Han SK, Werner P, Cohen G, Olanow CW.

J Pharmacol Exp Ther. 1998 Feb;284(2):700-6.

PMID:
9454817
20.

L-deprenyl protects mesencephalic dopamine neurons from glutamate receptor-mediated toxicity in vitro.

Mytilineou C, Radcliffe P, Leonardi EK, Werner P, Olanow CW.

J Neurochem. 1997 Jan;68(1):33-9.

21.
22.

L-DOPA up-regulates glutathione and protects mesencephalic cultures against oxidative stress.

Han SK, Mytilineou C, Cohen G.

J Neurochem. 1996 Feb;66(2):501-10.

PMID:
8592119
24.
25.

The Alzheimer amyloid precursor proteoglycan (appican) is present in brain and is produced by astrocytes but not by neurons in primary neural cultures.

Shioi J, Pangalos MN, Ripellino JA, Vassilacopoulou D, Mytilineou C, Margolis RU, Robakis NK.

J Biol Chem. 1995 May 19;270(20):11839-44.

26.

Human transplacental transfer of carbidopa/levodopa.

Merchant CA, Cohen G, Mytilineou C, DiRocco A, Moros D, Molinari S, Yahr MD.

J Neural Transm Park Dis Dement Sect. 1995;9(2-3):239-42.

PMID:
8527007
27.

Impaired oxidation of pyruvate in human embryonic fibroblasts after exposure to L-dopa.

Werner P, Mytilineou C, Cohen G, Yahr MD.

Eur J Pharmacol. 1994 Sep 22;263(1-2):157-62.

PMID:
7821347
28.

1-Methyl-4-phenylpyridinium-like neurotoxicity of a pyridinium metabolite derived from haloperidol: cell culture and neurotransmitter uptake studies.

Bloomquist J, King E, Wright A, Mytilineou C, Kimura K, Castagnoli K, Castagnoli N Jr.

J Pharmacol Exp Ther. 1994 Aug;270(2):822-30.

PMID:
8071874
29.

Impaired oxidative decarboxylation of pyruvate in fibroblasts from patients with Parkinson's disease.

Mytilineou C, Werner P, Molinari S, Di Rocco A, Cohen G, Yahr MD.

J Neural Transm Park Dis Dement Sect. 1994;8(3):223-8.

PMID:
7748465
30.

Toxic and protective effects of L-dopa on mesencephalic cell cultures.

Mytilineou C, Han SK, Cohen G.

J Neurochem. 1993 Oct;61(4):1470-8.

PMID:
8376999
32.
33.

EGF enhances the survival of dopamine neurons in rat embryonic mesencephalon primary cell culture.

Casper D, Mytilineou C, Blum M.

J Neurosci Res. 1991 Oct;30(2):372-81.

PMID:
1839162
34.

Ascorbic acid in mesencephalic cultures: effects on dopaminergic neuron development.

Kalir HH, Mytilineou C.

J Neurochem. 1991 Aug;57(2):458-64.

PMID:
2072096
35.

Lewy bodies in parkinsonism share components with intraneuronal protein bodies of normal brains.

Issidorides MR, Mytilineou C, Panayotacopoulou MT, Yahr MD.

J Neural Transm Park Dis Dement Sect. 1991;3(1):49-61.

PMID:
1712207
37.

Mesencephalic dopamine neurons become less sensitive to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity during development in vitro.

Danias P, Nicklas WJ, Ofori S, Shen J, Mytilineou C.

J Neurochem. 1989 Oct;53(4):1149-55.

PMID:
2788714
38.

6-Hydroxydopamine toxicity to dopamine neurons in culture: potentiation by the addition of superoxide dismutase and N-acetylcysteine.

Mytilineou C, Danias P.

Biochem Pharmacol. 1989 Jun 1;38(11):1872-5. No abstract available.

PMID:
2735944
40.

The toxicity of MPTP to dopamine neurons in culture is reduced at high concentrations.

Friedman L, Mytilineou C.

Neurosci Lett. 1987 Aug 18;79(1-2):65-72.

PMID:
2890125
41.

Histochemical evaluation of glutathione in brain.

Slivka A, Mytilineou C, Cohen G.

Brain Res. 1987 Apr 21;409(2):275-84.

PMID:
3580876
42.

Tissue culture model for studying MPTP toxicity to dopamine neurons.

Mytilineou C, Cohen G.

Adv Neurol. 1987;45:145-8. No abstract available.

PMID:
3493622
43.
44.

1-Methyl-4-phenylpyridine (MPP+) is toxic to mesencephalic dopamine neurons in culture.

Mytilineou C, Cohen G, Heikkila RE.

Neurosci Lett. 1985 Jun 4;57(1):19-24.

PMID:
3875812
45.

Studies on the mechanism of action of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).

Cohen G, Mytilineou C.

Life Sci. 1985 Jan 21;36(3):237-42.

PMID:
3917526
46.

Pargyline and deprenyl prevent the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in monkeys.

Cohen G, Pasik P, Cohen B, Leist A, Mytilineou C, Yahr MD.

Eur J Pharmacol. 1984 Oct 30;106(1):209-10. No abstract available.

PMID:
6442232
47.
48.

Actin-stimulated myosin Mg2+-ATPase inhibition by brain protein.

Berl S, Chou M, Mytilineou C.

J Neurochem. 1983 May;40(5):1397-405.

PMID:
6131941
49.

Explant cultures of dog substantia nigra and striatum: a model for the study of nigro-striatal dopamine neurons.

Mytilineou C, Cohen G, Dembiec-Cohen D, Van Woert M, Hwang E.

J Neural Transm Suppl. 1983;19:37-51.

PMID:
6321649
50.

Pharmacodynamic properties of catecholamine-derived TIQ's and 7-O-methylated metabolites in neuronal systems.

Cohen G, Mytilineou C.

Prog Clin Biol Res. 1982;90:265-74. No abstract available.

PMID:
7111322

Supplemental Content

Loading ...
Support Center